Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity: 2012-2025

Historic Liabilities and Shareholders Equity for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $280.7 million.

  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity fell 25.47% to $280.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 22.51%. This contributed to the annual value of $280.7 million for FY2025, which is 25.47% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Liabilities and Shareholders Equity stood at $280.7 million, which was down 6.74% from $301.0 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $495.2 million in Q2 2023 and a low of $280.7 million during Q3 2025.
  • In the last 3 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $376.7 million in 2024 and averaged $377.7 million.
  • In the last 5 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity increased by 28.54% in 2023 and then fell by 25.47% in 2025.
  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $440.6 million in 2021, then dropped by 21.12% to $347.5 million in 2022, then climbed by 23.30% to $428.5 million in 2023, then declined by 18.64% to $348.6 million in 2024, then declined by 25.47% to $280.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $280.7 million for Q3 2025, versus $301.0 million for Q2 2025 and $323.0 million for Q1 2025.